Call Text Chat Email Refer a Patient Join a Study

Search

MotherToBaby

Medications and More during pregnancy and breastfeeding

​​Thalidomide​ (Thalomid®)

Selected References:

  • Brooks C, et al. 1977. Linear growth of children with limb deformities following exposure to thalidomide in utero. Acta Paediatr Scan, 66:673-675.  
  • Castilla E, et al. 1996. Thalidomide, a current teratogen in South America. Teratology, 54:273-277.  
  • Gao S, et al. 2020. Recent advances in the molecular mechanism of thalidomide teratogenicity. Biomed Pharmacother, 127:110114.  
  • Guo L, et al. 2023. Inflammatory bowel disease can reduce ovarian reserve function in women: a systematic review and meta-analysis. Medicine (Baltimore), 102(11):e33113.  
  • Gollop T, et al. 1987. Prenatal diagnosis of thalidomide syndrome. Prenat Diagn, 7:295-298.  
  • Ito T, et al. 2020. Molecular mechanisms of thalidomide and its derivatives. Proc Jpn Acad Ser B Phys Biol Sci, 96(6):189-203. 
  • Klein-Weigel PF, Ding-Greiner C. 2025. Cardiovascular manifestations of thalidomide embryopathy. Vasa, 54(5):299-304.  
  • Mahesri M, et al. 2024. Trends in use and evidence of adherence to risk evaluation and mitigation strategy pregnancy testing requirements for thalidomide, lenalidomide, and pomalidomide in the USA, 2000-2020. Drug Saf, 47(9):909-919.  
  • Miller MT, et al. 2009. Thalidomide and misoprostol: opthalmologic manifestations and associations both expected and unexpected. Birth Defects Res A Clin Mol Teratol, 85(8):667-676.  
  • Peng X, et al. 2017. Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients. Medicine (Baltimore), 96(21):e6540.  
  • Prescriber Guide to (THALOMID REMS™ ) Risk Evaluation and Mitigation Strategy (REMS)™ Program. (2014). Retrieved from https://www.fda.gov/media/79047/download 
  • Rodier PM, 2000. The early origins of autism. Scientific American, 282:56-63.  
  • Rodier PM. 2002. Converging evidence for brain stem injury in autism. Dev Psychopathol, 14(3):537-557. 
  • Smithells R. 1992. Recognition of thalidomide defects. J Med Genet, 29:716-723.  
  • Sterling D, et al. 1997. Thalidomide: a surprising recovery. J Am Pharm Assn, 3:306-313.  
  • Stromland K, et al. 1993. Thalidomide embryopathy: revisited 27 years later. Acta Ophthalmol (Copen), 71:238-245.  
  • Stromland K, et al. 1994 Autism in the thalidomide embryopathy: a population study. Dev. Med. Child Neurol, 36:351-356.  
  • Vargesson N. 2019. The teratogenic effects of thalidomide on limbs. J Hand Surg Eur Vol, 44(1):88-95.  
  • Xiang P, et al. 2023. Clinical characteristics and risk factors of ovarian reserve decreases in women with Crohn’s disease: a case-control study. J Ovarian Res, 16(1):34.  

 

 

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.